Preterm Birth and Prelabor Rupture Of Membranes (PROM) Testing Market Size Hit USD 2.17 Billion at a CAGR of 2.8% In 2032

The global preterm birth and Prelabor Rupture of Membranes (PROM) testing market size was USD 1.69 Billion in 2022 and is expected to register a revenue CAGR of 2.8% over the forecast period, according to the latest report by Reports and Data.

Preterm birth is a major cause of infant mortality and morbidity, responsible for over 35% of newborn deaths globally. To address the increasing number of preterm births, healthcare providers are adopting Preterm Birth and PROM Testing, a non-invasive prenatal test that can detect PROM in pregnant women.

The market for non-invasive prenatal diagnostic procedures is also expected to grow due to the rising demand for safer prenatal testing. Non-Invasive Prenatal Testing (NIPT) is a popular prenatal testing method that uses cell-free Deoxyribonucleic Acid (cfDNA) from the mother’s blood to detect genetic abnormalities and illnesses in the developing fetus, without the risks associated with invasive testing procedures like amniocentesis. This makes it a preferred choice among pregnant women.

Moreover, the increasing adoption of advanced prenatal diagnostic technologies is driving the growth of the market. With the advancements in technology, newer and better prenatal testing procedures like cfDNA testing and Next-Generation Sequencing (NGS) have been developed, making prenatal testing more accurate and reliable. This has led to a wider application of these technologies in the healthcare sector.

The market for preterm birth and PROM Testing is experiencing growth due to a rise in demand from different end-use sectors such as hospitals, diagnostic labs, and research institutions. This has resulted in increased revenue for the market. For instance, Mayo Clinic and Natera, a well-known company providing genetic testing and diagnostics, have partnered to create and market innovative non-invasive prenatal tests for the early identification of preterm birth and other pregnancy-related conditions in 2020.

Companies profiled in the market report are The 3M Company, Dentsply Sirona, Envista, Align Technology, Inc., Argen.com., TP Orthodontics, Inc., Henry Schein, Inc., Institut Straumann AG, SmileDirectClub, and Angel Aligner.

Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/6018

Market Overview:

The research report assesses the market dynamics, market landscape, company profiles, production and manufacturing capacity, year-on-year growth rate, SWOT analysis, and Porter’s Five Forces analysis. The report estimates the market size, market growth, and provides an accurate forecast for the key segments of the market for the forecast period of 2022-2032. The report also covers an in-depth analysis of the key competitors of the market, along with their growth strategies and business expansion plans.

The Preterm Birth and Prelabor Rupture Of Membranes (PROM) Testing Market has been segmented into key regions of the world and offers an analysis of growth rate, market share, market size, current and emerging trends, production and consumption ratio, industrial chain analysis, demand and supply, import and export, revenue contribution, and presence of key players in each region. A country-wise analysis of the market is offered in the report to gain a better understanding of the regional spread and progress of the Preterm Birth and Prelabor Rupture Of Membranes (PROM) Testing Market.

Further key findings from the report suggest,

• The global market for testing preterm birth and premature rupture of membranes (PROM) is expected to see significant revenue growth in the coming years, with the foetal fibronectin test projected to be the main contributor. This is due to the rising incidence of preterm birth, and the need for accurate and effective diagnostic tools. The foetal fibronectin test, which detects a protein produced by foetal membranes that indicates preterm delivery, is widely used for diagnosing preterm labour and PROM.
• The 23-week segment is expected to generate a significant portion of revenue in the global market for preterm birth and PROM testing over the forecast period. This is because newborns born extremely prematurely have a high mortality rate, with less than 5% surviving if born before 23 weeks, according to the Centers for Disease Control and Prevention (CDC). Therefore, it is crucial to diagnose and treat preterm birth and PROM at an early stage in this particular population.
• The North American market is expected to have the largest revenue share in the global market for preterm birth and PROM testing, as a result of rising rates of premature births. In the United States, approximately 10% of all live births are classified as preterm, according to the Centers for Disease Control and Prevention (CDC).
• Some of the prominent players profiled in the global preterm birth and PROM testing market include Abbott Laboratories, Alere Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics, Sera Prognostics, Inc., Cooper Surgical, Inc., Quidel Corporation, and NanoEntek.
• On March 3, 2021, Cooper Surgical, Inc. acquired the prenatal and perinatal products division of Safe Obstetric Systems, a company that manufactures medical devices. This acquisition will broaden Cooper Surgical’s portfolio of products in the field of obstetrics and gynecology.
• On June 26, 2020, LabCorp introduced the Panorama Test, a non-invasive prenatal test. The test detects chromosomal abnormalities using cell-free DNA technology and is suited for use in high-risk pregnancies.

To understand how our Preterm Birth and Prelabor Rupture Of Membranes (PROM) Testing Market can bring difference to your business strategy:– https://www.reportsanddata.com/report-detail/preterm-birth-and-prelabor-rupture-of-membranes-prom-testing-market

For the purpose of this report, Reports and Data has segmented the global preterm birth and PROM testing market on the basis of Product Type Outlook, Test Type Outlook, Gestational Age Outlook, End-use Outlook, and Regional Outlook:

 Product Type Outlook (Revenue, USD Billion; 2022 – 2032)

• Instruments
• Consumables
• Services

Test Type Outlook (Revenue, USD Billion; 2022 – 2032)

• Fetal Fibronectin Test
• Ureaplasma Testing
• Others

Gestational Age Outlook (Revenue, USD Billion; 2022 – 2032)

• <23 weeks
• 23-33 weeks
• >33 weeks

End-use Outlook (Revenue, USD Billion; 2022 – 2032)

• Hospitals
• Clinics
• Diagnostic Laboratories

Regional Outlook (Revenue, USD Billion; 2022-2032)

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Sweden
  • BENELUX
  • Rest of Europe
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Rest of LATAM
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Israel
  • Rest of MEA

Request a customization of the report : https://www.reportsanddata.com/request-customization-form/6018

 Key Advantages of Preterm Birth and Prelabor Rupture Of Membranes (PROM) Testing Market Report:

• Identification and analysis of the market size and competition
• Qualitative and quantitative analysis of the market data
• Data validated by industry experts after extensive primary and secondary research
• Extensive regional analysis of the Preterm Birth and Prelabor Rupture Of Membranes (PROM) Testing industry
• Profiling of key players along with their business overview, business strategies, deals and partnerships, and product portfolio
• SWOT and Porter’s Five Forces Analysis for in-depth understanding of the competitive landscape
• Feasibility analysis and investment analysis to enable strategic investment decisions
• Analysis of opportunities, drivers, restraints, challenges, risks, and limitations

Conclusively, all aspects of the Preterm Birth and Prelabor Rupture Of Membranes (PROM) Testing Market are quantitatively as well qualitatively assessed to study the global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects.

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:

John W
Head of Business Development
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Reports and Data | Web: www.reportsanddata.com
Check our upcoming research reports @ https://www.reportsanddata.com/upcoming-reports
Visit our blog for more industry updates @ https://www.reportsanddata.com/blogs

Image Credit

https://www.biospace.com/article/rise-in-reimbursement-policies-for-scar-treatment-is-expected-to-drive-hypertrophic-scar-treatment-market-growth-by-2030-says-reports-and-data/

https://www.biospace.com/article/increased-prevalence-of-morquio-syndrome-is-anticipated-to-drive-morquio-syndrome-treatment-market-growth-by-2030-says-reports-and-data/

https://www.biospace.com/article/increase-in-elderly-population-is-expected-to-drive-pagets-disease-treatment-market-growth-by-2030-says-reports-and-data/

https://www.biospace.com/article/increase-in-demand-for-appropriate-treatment-for-rare-diseases-is-expected-to-drive-herpes-simplex-treatment-market-revenue-growth-by-2030-says-reports-and-data/

https://www.biospace.com/article/growing-elderly-and-geriatric-population-is-expected-to-drive-hyperlipidemia-treatment-market-growth-by-2030-says-reports-and-data/

The post Preterm Birth and Prelabor Rupture Of Membranes (PROM) Testing Market Size Hit USD 2.17 Billion at a CAGR of 2.8% In 2032 appeared first on Market O Graphics.